5-Amino-1MQ is a small molecule studied for its inhibition of the enzyme NNMT, and has become a frequent subject of metabolic and cellular-energy research. This article provides an educational overview of what the published scientific literature reports about 5-Amino-1MQ, its mechanism, and the current state of the evidence. All information below is provided strictly for research and informational purposes.
What is 5-Amino-1MQ?
5-Amino-1MQ (full chemical name 5-amino-1-methylquinolinium) is a synthetic small-molecule compound. Notably, and unlike most compounds studied in this space, it is not a peptide — it is a small quinolinium derivative. Research literature also notes it is orally bioavailable, distinguishing it from peptide compounds that require other routes of administration in study models. It is typically supplied as a powder for research use.
Mechanism of interest
Scientific interest in 5-Amino-1MQ centres on its selective inhibition of nicotinamide N-methyltransferase (NNMT), an enzyme reported to be expressed at elevated levels in white adipose tissue and implicated in metabolic research. The published literature describes the mechanism as follows:
- NNMT inhibition — 5-Amino-1MQ binds competitively to the active site of NNMT, slowing the methylation of nicotinamide to 1-methylnicotinamide.
- NAD+ salvage pathway — because that reaction consumes nicotinamide (an NAD+ precursor), inhibiting it is studied for its association with increased intracellular NAD+ in research models.
- SAM preservation — the same reaction consumes S-adenosylmethionine (SAM), the cell's universal methyl donor, so NNMT inhibition is also studied in relation to cellular methylation capacity.
- Sirtuin and mitochondrial signalling — elevated NAD+ is studied in connection with sirtuin (SIRT1-7) activity and mitochondrial oxidative processes.
Researchers note this mechanism is distinct from that of incretin-based compounds such as GLP-1 receptor agonists, which act on receptor pathways rather than on enzyme-mediated NAD+ and methylation pools.
What the research has reported
NNMT was first identified as a metabolic research target in a 2014 paper published in Nature Communications. Subsequent work has examined small-molecule NNMT inhibitors, including 5-Amino-1MQ, in animal models. Published studies in diet-induced obese mice have reported reductions in body weight and adipose mass, with researchers noting the observed changes were associated with energy expenditure rather than altered food intake. Later studies published in Scientific Reports (2021 and 2022) examined NNMT inhibition alongside dietary intervention in the same animal model.
Critically, researchers consistently emphasise that the evidence base for 5-Amino-1MQ consists entirely of animal and in-vitro studies. No human clinical trial data has been published, and the gap between rodent findings and human outcomes remains an important limitation of the current literature. Published pharmacokinetic data is also limited to rodent studies.
Regulatory status in Australia
5-Amino-1MQ has not been approved by the Therapeutic Goods Administration (TGA), is not listed on the Australian Register of Therapeutic Goods (ARTG), and is not approved for therapeutic use in any country. There is no approved product label for this compound anywhere. It is supplied strictly as a research compound.
Important disclaimer
This article is provided for informational and laboratory-research purposes only. 5-Amino-1MQ is supplied strictly as a research compound, for in-vitro laboratory research use only. It is not for human or animal consumption. Nothing in this article constitutes medical advice, nor a recommendation for use in humans. Always refer to current published literature and applicable regulations.